Skip to main content
. 2017 Jul 5;19(12):1661–1672. doi: 10.1093/neuonc/nox122

Fig. 6.

Fig. 6

PFS for the 145 evaluable patients on the SIOP-CNS-GCT-96 protocol by end-of-treatment status (93 patients without residual tumor vs 52 with residual).